PolyNovo Limited (PNV) Fair Value & Analysis
Healthcare · AU · Market cap A$729M
Fair value as of: Jun 24, 2026
From 14 valuation models · updated 6 days ago
Share price −24.6% over the past month.
Price vs Fair Value (12 months)
12‑month range A$0.9035 – A$1.68 · fair‑value band A$0.2400 – A$0.4100 · the A$0.9500 price screens above the A$0.3300 fair value. As of Jun 24, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
PolyNovo Limited (PNV) currently trades at A$0.9500, while our model-based Fair Value estimate is A$0.3300 — implying the stock looks roughly 65.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, PolyNovo Limited generated revenue of A$139M at a net margin of 7.1%. Revenue grew 18.1% year over year. It earns a return on equity of 12.5%. The balance sheet holds a net cash position of A$16.4M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; Beta Cell implant, a novel intracutaneous ectopic pancreas to treat type 1 diabetes; NovoSorb MTX for single stage grafting in burns, chronic, and surgical wounds; and plastics and reconstructive device products. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PolyNovo Limited reported revenue of A$127M in FY2025 versus A$29.2M in FY2021, a compound +44.5%/yr. Reported net income was A$13.2M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABTT34 | R$39.41 | R$30.42 | -23% |
| Stryker Corporation S1YK34 | R$79.18 | R$43.78 | -45% |
| Medtronic plc MDT | $81.67 | $60.02 | -27% |
| Boston Scientific Corporation B1SX34 | R$229.30 | R$43.33 | -81% |
| Edwards Lifesciences Corporation EW | $85.98 | $41.02 | -52% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PolyNovo Limited (PNV) undervalued?
What is the fair value of PNV?
What is the quality score of PNV?
What is the revenue of PolyNovo Limited (PNV)?
What is the net profit margin of PNV?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.